Caribou Biosciences, Inc.
CRBUNASDAQHealthcareBiotechnology
Previous close
$1.66
+$0.05 · +3.11%
CRBU company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
42
Fair Value
Momentum
57
Neutral
Sentiment
43
Mixed
Risk resilience
21
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCaribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Rachel E. Haurwitz
- Listed since
- Jul 23, 2021
- Employees
- 97
Market position
Day range
Current $1.66
52-week range
Current $1.66
- Open
- $1.67
- Previous close
- $1.61
- Volume
- 1.16M
- 0.65× average
- Average volume
- 1.79M
- Average daily volume
- Market cap
- 164.64M USD
- Beta
- 2.28
- Market reference 1
- 50-day average
- $1.665
- -0.30% below average
- 200-day average
- $1.8157
- -8.58% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 163.36M USD
- P/E (TTM)
- -1.54×
- P/B (TTM)
- 1.71×
- P/S (TTM)
- 16.41×
- EV / EBITDA
- -1.13×
- Earnings yield
- -99.75%
- Free cash flow yield
- -75.66%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- -129.70%
- Operating margin
- -1090.90%
- Net margin
- -1030.42%
- Return on equity
- -121.24%
- Return on assets
- -84.47%
- Return on invested capital
- -89.77%
Financial health
- Debt / equity
- 0.27×
- Current ratio
- 5.71×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 11.16M USD | 9.99M USD | 34.48M USD | 13.85M USD | 9.6M USD |
| Cost of goods sold | 3.65M USD | 3.93M USD | 3.53M USD | 3.64M USD | 984K USD |
| Gross profit | 7.51M USD | 6.07M USD | 30.95M USD | 10.21M USD | 8.61M USD |
| Research and development | 109.44M USD | 130.15M USD | 112.08M USD | 82.23M USD | 52.26M USD |
| Selling, general, and administrative | 37.91M USD | 46.46M USD | 38.46M USD | 38.02M USD | 23.34M USD |
| Operating expenses | 143.71M USD | 172.68M USD | 147.01M USD | 116.61M USD | 75.59M USD |
| Interest income | 8M USD | — | 10.7M USD | 4.6M USD | 148K USD |
| Interest expense | — | — | — | — | 8K USD |
| Depreciation and amortization | 3.65M USD | 3.93M USD | 3.53M USD | 3.64M USD | 984K USD |
| Operating income | −136.19M USD | −166.62M USD | −116.06M USD | −106.4M USD | −66.98M USD |
| Net income | −148.13M USD | −149.11M USD | −102.07M USD | −99.42M USD | −66.92M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 73%
- 8 beats, 2 misses, 1 met estimate
- Average EPS surprise
- +1.73%
- 11 comparable reports
- Latest EPS result
- -0.24
- Estimate -0.32 · Beat by 25.93%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
9 ratingsCRBU peers
ETFs holding CRBU
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.4M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM3.63M0.00%81.62B USD0.19%$299.96+0.77%
Vanguard Extended Market ETFVXF1.63M0.00%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Value ETFIWN1.41M0.01%14.66B USD0.24%$224.81+0.45%
iShares Biotechnology ETFIBB1.07M0.01%10.75B USD0.44%$213.56+1.29%
Vanguard Russell 2000 ETFVTWO755.62K0.00%17.4B USD0.06%$121.25+0.74%
Schwab U.S. Small-Cap ETFSCHA682.59K0.00%23.1B USD0.03%$34.83+0.52%
Fidelity Enhanced Small Cap ETFFESM514.76K0.01%6.03B USD0.28%$47.94+0.80%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 4.4M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 3.63M
- Weight
- 0.00%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Extended Market ETFVXF- Market value
- 1.63M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Value ETFIWN- Market value
- 1.41M
- Weight
- 0.01%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
iShares Biotechnology ETFIBB- Market value
- 1.07M
- Weight
- 0.01%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Vanguard Russell 2000 ETFVTWO- Market value
- 755.62K
- Weight
- 0.00%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 682.59K
- Weight
- 0.00%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
Fidelity Enhanced Small Cap ETFFESM- Market value
- 514.76K
- Weight
- 0.01%
- AUM
- 6.03B USD
- Expense ratio
- 0.28%
- Price / 1D
- $47.94+0.80%
Continue in GoAI
Research CRBUresearch.disclaimer